Tag: Kadcyla

Antibody–drug conjugates (ADCs) have transformed targeted cancer therapy by enabling the selective delivery of cytotoxic agents to tumor cells, sparing healthy tissue. The design of ADCs allows for higher doses of the cytotoxic drug to be administered, potentially increasing efficacy. They are currently considered the most promising drug classes in oncology, with ongoing efforts to expand their use for non-oncological indications and in combination therapies.

Economy: Failure to Reshore Pharmaceutical Manufacturing: US Approved Drug Manufacturing Shifts to Europe as US Deal Volume Drops

The U.S. Food and Drug Administration (FDA) has approved additional indications for the Roche PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody and VENTANA HER2 Dual ISH DNA Probe Cocktail tests.

Compelling evidence presented at the European Society of Medical Oncology (ESMO) Congress, being held October 17-21, 2025, in Berlin, Germany, has shown that a new generation of antibody-drug conjugates (ADCs) can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.

Clinical Study finds ADCs to be Highly Effective in Preventing Recurrence in Patients with Early Stage HER2+ Breast Cancer

Creating A Strong ADC Pipeline: AbbVie Agrees to Acquires ImmunoGen for $10.1 Billion

With renewed focus and commitment in creating a platform for innovative scientific insights and transformative experiences, 13th World ADC in London, held March 13...

Trastuzumab deruxtecan is revolutionizing the treatment paradigm. Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd; Enhertu®; Daiichi Sankyo and AstraZeneca) led to higher response rates and longer survival...

The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with unresectable or metastatic HER2...

Antibody-drug conjugates (ADCs) as precision targeted cancer therapies have started to deliver on their early promise as an innovative novel drug modality as demonstrated...